Connection

NICOLA HANANIA to Drug Therapy, Combination

This is a "connection" page, showing publications NICOLA HANANIA has written about Drug Therapy, Combination.
Connection Strength

2.288
  1. Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
    View in: PubMed
    Score: 0.660
  2. POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes. Chest. 2024 Jul; 166(1):12-17.
    View in: PubMed
    Score: 0.182
  3. Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
    View in: PubMed
    Score: 0.174
  4. Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opin Emerg Drugs. 2017 09; 22(3):285-299.
    View in: PubMed
    Score: 0.113
  5. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.110
  6. Role of anticholinergics in asthma management: recent evidence and future needs. Curr Opin Pulm Med. 2015 Jan; 21(1):103-8.
    View in: PubMed
    Score: 0.094
  7. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.079
  8. New bronchodilators. Curr Opin Pharmacol. 2012 Jun; 12(3):238-45.
    View in: PubMed
    Score: 0.078
  9. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
    View in: PubMed
    Score: 0.076
  10. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.073
  11. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.064
  12. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008; 21(3):540-50.
    View in: PubMed
    Score: 0.058
  13. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc. 2007 Oct 01; 4(7):526-34.
    View in: PubMed
    Score: 0.057
  14. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct; 29(10):2121-33.
    View in: PubMed
    Score: 0.057
  15. The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
    View in: PubMed
    Score: 0.049
  16. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy. 2004 Sep; 3(3):271-7.
    View in: PubMed
    Score: 0.046
  17. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.043
  18. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
    View in: PubMed
    Score: 0.043
  19. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 08; 162(2):297-308.
    View in: PubMed
    Score: 0.039
  20. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
    View in: PubMed
    Score: 0.035
  21. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
    View in: PubMed
    Score: 0.035
  22. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019 Jul - Aug; 154:86-92.
    View in: PubMed
    Score: 0.032
  23. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
    View in: PubMed
    Score: 0.024
  24. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
    View in: PubMed
    Score: 0.019
  25. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 02; 155(3):179-91.
    View in: PubMed
    Score: 0.019
  26. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
    View in: PubMed
    Score: 0.017
  27. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.